Spexis AG

POLN

CH0106213793

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:30 2024-04-26 am EDT			5-day change	1st Jan Change
0.059 ^CHF	+0.34%		+7.27%	+43.90%

Apr. 17	Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	MT
Apr. 17	Swiss Court OKs Moratorium Extension for Spexis	MT

EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation

December 28, 2021

EnBiotix, Inc. announced that it has received $11 million in a round of funding on December 29, 2021. The transaction included participation from Vectura Group plc, Cystic Fibrosis Foundation, and returning investor Sanford Biosciences LLC. The company issued convertible note in the transaction.

Latest news about Spexis AG

Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis	Apr. 17	MT
Swiss Court OKs Moratorium Extension for Spexis	Apr. 17	MT
Basilea Pharmaceutica Receives Grant for Antibiotics Program	Apr. 09	MT
Ascom Hires New CFO	Mar. 21	MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	Feb. 08	MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	Jan. 15	MT
Spexis Secures Debt-restructuring Moratorium From Swiss Court	Dec. 05	MT
Spexis Seeks Loan Restructuring to Support Cystic Fibrosis Drug Study	Nov. 29	MT
Spexis to File for Debt-restructuring Moratorium in Switzerland; Stock Sinks	Nov. 08	MT
Spexis CFO to Step Down, Interim CFO Named	Nov. 01	MT
Spexis AG Announces Executive Changes, Effective December 1, 2023	Nov. 01	CI
Muriel Fleming Joins Spexis AG as Executive Committee, Effective December 1, 2023	Nov. 01	CI
Transcript : Polyphor AG - Special Call	23-10-09
Spexis Posts Lower H1 Attributable Loss	23-09-29	MT
Spexis AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-29	CI
Spexis AG Announces Appointment of Gonçalo Bernardes as Acting Head of Chemical Biology	23-09-28	CI
Spexis Secures Investment Pledge from SPRIM Global, Other Investors for ColiFin Trial	23-08-15	MT
Spexis AG announced that it has received $2.5 million in funding from SPRIM Ventures and other investors	23-08-13	CI
Spexis Enlists Financial Adviser to Evaluate Strategic Alternatives, Fundraising Opportunities	23-06-30	MT
Spexis AG Announces the Publication of Preclinical Results from its Novel Class of Macrocyclic, Peptidomimetic Antibiotics Developed in Collaboration with the University of Zurich	23-06-07	CI
Spexis AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-30	CI
Spexis Posts Higher FY22 Attributable Net Loss; Operating Loss Widens	23-05-30	MT
Destiny Pharma picks interim CEO as Clark makes quick exit	23-05-25	AN
Spexis Receives Extension for Publication of 2022 Annual Report	23-04-28	MT
Spexis AG announced that it has received $4.5 million in funding from SPRIM Ventures	23-04-17	CI

Chart Spexis AG

Duration

Period

More charts

Company Profile

Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.

Sector

Pharmaceuticals

Calendar

2024-09-04 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SPEXIS AG	+43.90%	4.36M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals

Spexis AG

Equities

POLN

CH0106213793

Pharmaceuticals

EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation

Latest news about Spexis AG

Chart Spexis AG

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Biopharmaceuticals